Horizon could have blockbuster in HZN-825
"Horizon could have blockbuster in HZN-825, says Jefferies 06/29:
HZNP Jefferies analyst David Steinberg noted Horizon Therapeutics recently acquired Curzion for a Phase 2 asset, now called HZN-825, that is targeting diffuse cutaneous systemic sclerosis, or dcSSc, which currently has no FDA approved treatment. While early, HZN-825 has shown encouraging safety and efficacy signals in trials, said Steinberg, who estimates peak sales for the drug of $540M, or $1.4B in peak sales in an upside scenario if the drug is "truly disease modifying." The analyst, who has not included '825 in his model without confirmatory Phase 2 data and notes that '825 is not in street estimates yet either, has a Buy rating and $63 price target on Horizon shares."